

Concepts in Vaccine Development

Editor

Stefan H. E. Kaufmann



Walter de Gruyter · Berlin · New York 1996

Contents

1.	The Need for New Vaccines	1
1.1	Vaccines as Evolutionary Tools: The Virulence-Antigen Strategy	1
	<i>Paul W. Ewald</i>	
1.1.1	Introduction	1
1.1.2	Application to Specific Pathogens	3
1.1.2.1	<i>Corynebacterium diphtheriae</i>	3
1.1.2.2	<i>Bordetella pertussis</i>	5
1.1.2.3	<i>Haemophilus influenzae</i>	8
1.1.2.4	<i>Streptococcus pneumoniae</i>	14
1.1.2.5	<i>Vibrio cholerae</i>	14
1.1.3	Guidelines for the Virulence-Antigen Strategy	15
1.1.3.1	Virulence, Cross-Protection, and Antigen Selection	15
1.1.3.2	Compliance, Age, and Vaccination	17
1.1.3.3	A Global Long-Term View	18
	Acknowledgements	20
	References	20
1.2	Economic Perspectives on Vaccine Needs	27
	<i>Robert V. Ashley and Christopher J. L. Murray</i>	
1.2.1	Introduction	27
1.2.2	The Role for Existing Vaccines	28
1.2.2.1	Cost-Effectiveness Analysis and Cost-Benefit Analysis	30
1.2.2.2	Assessing Costs	31
1.2.2.2.1	Costing Perspectives	31
1.2.2.2.2	Opportunity Cost	32
1.2.2.2.3	Calculations of Costs	32
1.2.2.2.4	Interpretations of Cost Data	33
1.2.2.3	Assessing Effectiveness	35
1.2.2.3.1	Mortality	36
1.2.2.3.2	Non-Fatal Health Outcomes	36
1.2.2.3.3	Other Value Judgments in Health Outcome Measures	38
1.2.2.4	The Cost-Effectiveness of Vaccines	40
1.2.2.4.1	Vaccine Cost-Effectiveness and Incidence of Disease	40

1.2.2.4.2	Results from the Health Sector Priorities Review	41
1.2.2.4.3	Results from the Center for Risk Analysis	45
1.2.2.5	Resource Allocation	47
1.2.3	Economic Appraisal of Vaccine Research Priorities	49
1.2.3.1	The Institute of Medicine Study	51
1.2.3.2	The Children's Vaccine Initiative Study	53
1.2.3.3	The World Health Organization's Ad Hoc Committee on Health Research	54
1.2.3.3.1	Identifying Research Needs Based on Present and Future Burdens of Disease	55
1.2.3.3.2	The Global Burden of Disease Study	55
1.2.4	Research Opportunities	64
	Acknowledgments	65
	References	65
1.3	Future Immunization Strategies – Considerations from the Public Health View	71
	<i>Sieghart Dittmann</i>	
1.3.1	Introduction	71
1.3.2	Global Health Situation	71
1.3.2.1	Health Situation in Industrialized Countries	72
1.3.3	Current Immunization Programmes – Programme Development and Design, Goals and Successes, Constraints and Lessons Learned	74
1.3.3.1	Programme Development and Design	74
1.3.3.2	Successes of Current Immunization Programmes	76
1.3.3.3	Constraints and Lessons Learned	79
1.3.3.3.1	Maintenance of High Coverage	79
1.3.3.3.2	Disease Surveillance is Fundamental for Monitoring Immunization Programmes	79
1.3.3.3.3	Laboratory Network	80
1.3.3.3.4	Vaccine Demand, Supply, Financing and Quality Control	80
1.3.3.3.5	Logistics and Cold Chain	81
1.3.4	Vaccine Research	81
1.3.5	Future Immunization Programmes	82
1.3.5.1	Available and Needed Vaccines	85
1.3.5.2	New or Simplified Approaches for Vaccine Administration	85
1.3.5.2.1	Combined Vaccines	85
1.3.5.2.2	Controlled Release Vaccines	87
1.3.5.3	Optimal Use of EPI Experience	87
	References	87

Contents	XI
1.4 The New Pertussis Vaccines	89
<i>David L. Klein and Carole Heilman</i>	
1.4.1 Introduction	89
1.4.2 Background: The Disease	89
1.4.3 The Whole Cell Vaccine	90
1.4.3.1 Safety	90
1.4.3.2 Efficacy	91
1.4.4 New Candidate Vaccines	93
1.4.4.1 Acellular Vaccine Composition	93
1.4.4.2 Clinical Studies	98
1.4.5 Future Impact	105
References	110
 2. General Principles of Immunology	117
2.1 Basic Principles of Immunity Against Intracellular Bacteria and Protozoa	117
<i>Gudrun Szalay and Stefan H. E. Kaufmann</i>	
2.1.1 Introduction	117
2.1.2 Specific Immune Response	118
2.1.2.1 MHC and Antigen Presentation	119
2.1.2.2 T Cells	122
2.1.2.2.1 T _H Functions	123
2.1.2.2.2 Cytolytic Functions	125
2.1.3 T _{H1} Function and Cytolysis in Intracellular Microbial Infections	126
2.1.4 Innate Immune Mechanisms	126
2.1.5 Evasion Mechanisms of Pathogens	129
2.1.6 Specific Problems	130
2.1.7 Vaccine Development	131
2.1.8 Concluding Remarks	133
Acknowledgements	133
References	134
 2.2 Viral Immunity and Vaccine Strategies	141
<i>David L. Woodland, Geoffrey A. Cole and Peter C. Doherty</i>	
2.2.1 Characteristics of the Pathogen	141
2.2.1.1 Multi-Host Viruses with a Systemic Pathogenesis	141
2.2.1.2 Viruses with a Mucosal Entry but a Systemic Pathogenesis	143
2.2.1.3 Viruses That Cause Severe Pathology at Mucosal Surfaces	144
2.2.2 The Nature of Immune Memory	144
2.2.2.1 The Essential Difference Between T Cell and B Cell Memory	145
2.2.2.2 The Initiation of T Cell Memory	145

2.2.2.3	The Nature of B Cell Memory	146
2.2.2.4	The Antigen Persistence Debate	146
2.2.2.5	The Differentiation State of Memory T Cells	148
2.2.3	Secondary Stimulation and the Recall Response	148
2.2.3.1	The Effect of Antibody	149
2.2.3.2	Characteristics and Limitations of the Recall Response for Memory T Cells	150
2.2.4	Maintaining Effective T Cell Memory	150
2.2.4.1	Secondary Stimulation	151
2.2.4.2	Bystander Activation and Memory T Cell Loss	151
2.2.5	Vaccine Strategies Based on Priming CD8 ⁺ T Cells	152
2.2.6	Cytotoxic T Lymphocytes as Targets for Vaccines	153
2.2.7	Epitope Selection	155
2.2.8	Factors that Control Immunodominance	156
2.2.9	Subdominant Epitopes as Vaccine Targets?	157
2.2.10	Concluding Remarks	159
	Acknowledgements	160
	References	160
2.3	Broadly Reactive HLA Restricted T Cell Epitopes and Their Implications for Vaccine Design	169
	<i>John Sidney, Ralph T. Kubo, Peggy A. Wentworth, Jeff Alexander, Robert W. Chesnut, Howard M. Grey, and Alessandro Sette</i>	
2.3.1	General Introduction	169
2.3.2	A General Strategy for Vaccine Design	170
2.3.3	The Concept of Class I Supertypes	173
2.3.4	Pan DR Class II Epitopes (PADRE)	181
2.3.5	Concluding Remarks	182
	Acknowledgements	183
	References	183
2.4	Quantitative Considerations in the Design of Vaccination Strategies Against Pathogens Uniquely Susceptible to Cell-Mediated Attack	187
	<i>Peter Bretscher</i>	
2.4.1	Introduction	187
2.4.2	Pathophysiological Significance of Distinct Classes of Immunity and Their Exclusive Regulation	188
2.4.3	Basic Studies on Immune Class Regulation	189
2.4.4	Paradoxes of this View of Immune Class Regulation in Terms of Current Models for the Induction of Th Cells and a Potential Resolution	193

2.4.5	Dependence of the Class of Immunity Induced on Dose of Antigen Administered and on Time After Immunisation: Relevance to Establishing Cell-Mediated Immune Deviation	194
2.4.6	Establishing Low-Zone Cell-Mediated Immune Deviation to <i>L. major</i> in "Susceptible Mice"	195
2.4.7	The Dependence of the Generation of Th1 and Th2 Cells on Parasite Dose Appears to be General: Potential Implications for Universally Efficacious Vaccination	196
2.4.8	Further Quantitative Considerations	197
2.4.9	The Other Side of the Coin: Organ-Specific Immunity	198
2.4.10	Establishment of Resistance to Tumours by Excision Priming and its Potential Relationship to Cell-Mediated Low-Zone Immune Deviation	199
2.4.11	Problems in Vaccine Design Against Tuberculosis and Speculation on Potential Solutions	201
References		203
2.5	The Impact of the Type 1 and Type 2 T Helper Cell Concept on Novel Vaccine Design with Emphasis on Protection Against <i>Leishmania</i> Parasites	205
<i>Christian Bogdan and Martin Röllinghoff</i>		
2.5.1	Introduction	205
2.5.2	T Helper Cell Subpopulations and Infections with Intracellular Parasites	206
2.5.2.1	Basic Aspects of the Th1/Th2 Concept	206
2.5.2.2	Principles of the Immune Response to <i>Leishmania</i>	210
2.5.2.2.1	Mouse Model of <i>L. major</i> Infection	210
2.5.2.2.2	Human Cutaneous Leishmaniasis	216
2.5.2.2.3	Mouse Model of <i>L. donovani</i> Infection	217
2.5.2.2.4	Human Visceral Leishmaniasis (kala azar)	218
2.5.3	Vaccination Against <i>Leishmania</i>	219
2.5.3.1	General Considerations	219
2.5.3.1.1	Type of Antigen	220
2.5.3.1.2	Route of Antigen Application	223
2.5.3.1.3	Antigen Dose	224
2.5.3.1.4	Host Factors	224
2.5.3.2	Biochemical and Immunological Characterization of Protective <i>Leishmania</i> Antigens	224
2.5.3.3	Induction of Protective CD4 ⁺ T Lymphocytes by Combined Immunization with Antigens and Immunomodulators	228
2.5.4	Concluding Remarks	228
Acknowledgements		229
References		229

3.	General Principles of Vaccinology	243
3.1	Modern Adjuvants. Functional Aspects	243
	<i>Bror Morein, Karin Lövgren-Bengtsson and John Cox</i>	
3.1.1	Introduction	243
3.1.1.1	Experience with Conventional Adjuvant Formulations	243
3.1.2	Categories of Adjuvants	245
3.1.2.1	Characteristics of Some Adjuvant Formulations	245
3.1.2.2	Encapsulation and Slow-Release Formulations	248
3.1.2.3	Immunomodulators – One Part of the Adjuvant Formulation	248
3.1.3	Antigen Presentation and Targeting	249
3.1.3.1	Uptake and Intracellular Distribution of Ag in Antigen Presenting Cells	249
3.1.3.2	Adjuvant Influences the Transport of Ag and Localization of B and T Cell Responses Following Parenteral Immunization	250
3.1.3.2.1	Induction of CTL	251
3.1.3.3	Adjuvants and Delivery Systems for Induction of Mucosal Immunity	252
3.1.4	Vaccine-Disease Relationships	254
3.1.4.1	Requirement of Adjuvant for Parenterally Administered Vaccines for Prevention of Disease Caused by Mucosal Infections	254
3.1.4.2	Vaccines for Infants Requires That the Interference of Maternal Antibodies is Overcome	257
3.1.5	Future Adjuvant Formulations	257
	References	259
3.2	Biodegradable Microspheres as Vehicles for Antigens	265
	<i>Gideon F.A. Kersten and Bruno Gander</i>	
3.2.1	Introduction	265
3.2.2.	Biodegradable polymers	266
3.2.3.	Preparation Techniques of Microspheres	273
3.2.3.1	Solvent Evaporation/Extraction	275
3.2.3.2	Coacervation (or Organic Phase Separation)	277
3.2.3.3	Spray-Drying	278
3.2.4	Mode of Action	278
3.2.4.1	<i>In vitro</i> Release Kinetics	278
3.2.4.2	<i>In vivo</i> Processing	281
3.2.5	Parenteral Immunization	284
3.2.6	Local Immunization	287
3.2.7	Safety Issues and Quality Control	290
3.2.8	Conclusions and Prospects	292
	References	293

3.3	Peptide Based Vaccines	303
	<i>Hansjörg Schild and Hans-Georg Rammensee</i>	
3.3.1	Introduction	303
3.3.2	Induction of Immune Responses Using Synthetic Peptides	304
3.3.2.1	B Cell Responses Induced by Synthetic Peptides	304
3.3.2.2	T _H Cell Responses Induced by Synthetic Peptides	305
3.3.2.3	CTL Responses Induced by Synthetic Peptides	306
3.3.3	Identification and Prediction of T Cell Epitopes	307
3.3.3.1	Identification of the Protein	307
3.3.3.2	Identification of MHC Class I Restricted T Cell Epitopes	308
3.3.3.3	Identification of MHC Class II Restricted T Cell Epitopes	311
3.3.4	Administration of Peptides	315
3.3.4.1	Adjuvants	315
3.3.4.2	Delivery Systems	315
3.3.4.3	Lipopeptides	316
3.3.4.4	Protein Carriers	317
3.3.5	Dealing with MHC Polymorphism	318
3.3.6	Controlling the Efficacy	318
3.3.7	Conclusion	319
	References	319
3.4	Recombinant Bacteria as Vaccine Carriers of Heterologous Antigens	327
	<i>Carlos E. Hormaeche and C. M. Anjam Khan</i>	
3.4.1	Use of Live Attenuated Bacteria as Antigen Delivery Systems ...	327
3.4.2	Live Salmonella Vaccines	328
3.4.3	Live Salmonella Vaccines as Antigen Delivery Systems	330
3.4.4	Problems Encountered in the Expression of Recombinant Antigens in Salmonella Vaccines	331
3.4.5	Degradation of the Recombinant Antigen by Salmonella Proteases	332
3.4.6	Plasmid Stability and Level of Expression	333
3.4.6.1	Plasmid Loss	333
3.4.6.2	Impaired Persistence of the Vaccine	333
3.4.6.3	Stable <i>in vitro</i> , Unstable <i>in vivo</i>	334
3.4.6.4	Repeated Inoculations	334
3.4.6.5	Vaccine Strain Background	334
3.4.6.6	Repeated Passage	335
3.4.6.7	Removal of Toxic Subregions of the Antigen	335
3.4.6.8	Codon Optimization	335
3.4.6.9	Reducing the Expression Level with a Weaker Promoter	336
3.4.6.10	Incorporation of the Foreign Gene into the Salmonella Chromosome	336

3.4.6.11	Stabilisation by Incorporation of Essential Genes into Expression Plasmids	336
3.4.6.12	Incompatible Plasmids	337
3.4.6.13	“On-Off” Promoters	337
3.4.6.14	<i>In vivo</i> Inducible Promoters	337
3.4.7	Location of the Recombinant Antigen on the Bacterial Cell and Antigen Presentation	338
3.4.8	Examples of Multivalent Vaccine Strains	340
3.4.9	Expression of Recombinant Antigens as Fusions to Tetanus Toxin Fragment C (TetC) Driven from the Anaerobically Inducible <i>nirB</i> Promoter	345
3.4.10	Fusions of Repeating Epitopes to TetC	346
3.4.11	Preimmunisation with Tetanus Toxoid Did Not Decrease Vaccine Efficacy	346
3.4.12	Fusions of TetC and Antigens from Herpes Simplex Virus	347
3.4.13	Cytokines and Immunomodulation	347
3.4.14	Influence of the Host Background on the Response to Recombinant Antigens	348
3.4.15	Summary and Conclusions	348
	References	349
3.5	Genetic Detoxification of Bacterial Toxins	361
	<i>Rino Rappuoli and Mariagrazia Pizza</i>	
3.5.1	Introduction	361
3.5.2	Genetic Detoxification of Pertussis Toxin, Cholera Toxin and Heat-Labile Toxin	362
3.5.2.1	Structure of the Proteins	362
3.5.2.2	The Active Site of ADP-Ribosylating Toxins	364
3.5.3	Construction of the PT-9K/129G Non Toxic Derivative of PT ...	364
3.5.3.1	Clinical Development Shows the Superior Immunogenicity of PT-9K/129G	365
3.5.3.2	Genetically Detoxified PT is Effective in Protecting Against the Disease	370
3.5.4.	Genetic Detoxification of LT and CT	371
3.5.4.1	Non Toxic Mutants of CT and LT Induce Neutralizing Antibodies Against the A Subunit	371
3.5.4.2	Non Toxic Derivatives of LT are Mucosal Adjuvants	372
3.5.5	Conclusions	373
	References	374

3.6	Recombinant Virus as Vaccination Carrier of Heterologous Antigens	379
<i>Marion E. Perkus and Enzo Paoletti</i>		
3.6.1	Introduction	379
3.6.1.1	Advantages of Live Recombinant Viruses as Vaccines	379
3.6.2	Double Stranded DNA Viruses: Poxviruses	380
3.6.2.1	Poxviruses	380
3.6.2.1.1	Orthopoxvirus Vectors	380
3.6.2.1.2	Avipoxvirus Vectors	382
3.6.2.1.3	Poxvirus-Based Vaccine Candidates Against Human Immunodeficiency Virus (HIV) and Related Viruses	384
3.6.2.1.4	Poxvirus Recombinants and Tumor Therapy	385
3.6.2.2	Herpesviruses	385
3.6.2.2.1	Herpesvirus Vectors	386
3.6.2.2.1.1	Herpes Simplex Virus-1 as a Vector	387
3.6.2.3	Adenoviruses	388
3.6.2.3.1	Adenovirus Vectors	388
3.6.2.3.2	Recombinant Adenoviruses as Vaccines	389
3.6.2.3.3	Use of Recombinant Adenoviruses in Cancer Therapy	392
3.6.2.3.4	Use of Recombinant Adenoviruses in Gene Therapy	392
3.6.2.3.5	Use of Recombinant Adenoviruses as Suicide Vectors	394
3.6.2.3.6	Adenovirus Capsids as Delivery Vehicles	394
3.6.2.3.7	Animal Adenoviruses as Vectors	395
3.6.2.4	Bovine Papilloma Virus as a Vector for Gene Therapy	395
3.6.3	Single Stranded DNA Viruses as Vectors for Gene Therapy	396
3.6.4	RNA Viruses: Retroviruses	397
3.6.4.1	Retroviruses	397
3.6.4.1.1	Retroviruses as Vaccine Vectors	397
3.6.4.1.2	Use of Retroviral Vectors for Gene Transfer	397
3.6.4.1.3	Use of Retroviral Vectors in Cancer Therapy	398
3.6.4.1.4	Retroviruses as Suicide Vectors for Treatment of Brain Tumors ..	399
3.6.4.1.5	Recombinant Retroviruses in Treatment of HIV	400
3.6.4.1.6	Issues Related to the Use of Retroviral Vectors	400
3.6.4.2	Positive Strand RNA Viruses	401
3.6.4.2.1	Alphaviruses	401
3.6.4.2.2	Picornaviruses	402
3.6.4.2.2.1	Poliovirus Vectors	402
3.6.4.2.2.2	Poliovirus Vectors Expressing HIV Antigens	403
3.6.4.2.2.3	Other Picornaviruses Vectors	403
3.6.4.3	Negative Strand RNA Viruses	404
3.6.4.3.1	Paramyxoviruses as Vectors	404
3.6.4.3.2	Influenza Virus Vectors	405

3.6.4.3.2.1	Influenza Virus Vectors for Expression of Foreign Genes	405
3.6.4.3.3	Hepatitis Delta Virus as a Vector	406
3.6.5	Summary	407
	References	408
3.7	Naked DNA Vaccination	423
	<i>John W. Shiver, Jeffrey B. Ulmer, John J. Donnelly, and Margaret A. Liu</i>	
3.7.1	Introduction	423
3.7.2	Vaccine Plasmid Design	424
3.7.3	Formulation and Delivery of DNA	425
3.7.4	DNA Vaccine-Mediated Immunity	427
3.7.4.1	Humoral Immunity	427
3.7.4.2	Cellular Immunity	429
3.7.4.2.1	Generation of Anti-Viral CTL	429
3.7.4.2.2	Helper T Lymphocyte Responses	430
3.7.5	Protection in Animal Challenge Models	431
3.7.6	Conclusions and Future of DNA Vaccines	432
	References	433
3.8	Oral Vaccination, Mucosal Immunity and Oral Tolerance with Special Reference to Cholera Toxin	437
	<i>Jan Holmgren, Cecil Czerkinsky, Jia-Bin Sun and Ann-Mari Svennerholm</i>	
3.8.1	Introduction	437
3.8.2	Oral Vaccines Against Cholera and <i>E. coli</i> Diarrhea	438
3.8.2.1	Cholera Vaccines	439
3.8.2.2	ETEC Vaccine	441
3.8.3	Use of CTB as Carrier for Unrelated Vaccine Antigens	443
3.8.4	Oral Tolerance and Anti-Inflammatory Active Immunization	445
3.8.4.1	The Oral Tolerance Phenomenon	445
3.8.4.2	Medical Potential and Limitations	446
3.8.4.3	Cholera Toxin and Oral Tolerance	447
3.8.4.4	CTB and the Induction of Tolerance	447
3.8.4.5	Mechanisms of Tolerization	449
3.8.4.6	CTB-Tolerogen Conjugates for Immunotherapy	451
3.8.5	Conclusions	452
	Acknowledgements	453
	References	454

4.	Specific Vaccination Strategies	459
4.1	<i>Helicobacter pylori</i> : Pathogenic Determinants and Strategies for Vaccine Design	459
	<i>Paolo Ghiara, Antonello Covacci, John L. Telford and Rino Rappuoli</i>	
4.1.1	Introduction	459
4.1.1.1	The Second Decade of <i>H.pylori</i> : Relevance of Infection and Epidemiology Defined	461
4.1.1.2	The Fight Against Infection: Chemotherapy Versus Vaccination	462
4.1.1.3	Host-Parasite Interactions	462
4.1.1.3.1	<i>H.pylori</i> Adaptation to a Hostile Environment	462
4.1.1.3.2	Immune Response Against <i>H.pylori</i>	463
4.1.2	<i>H.pylori</i> Antigens and Their Potential as Vaccine Candidates	464
4.1.2.1	Antigens Common to Both Type I and Type II Strains	465
4.1.2.1.1	Urease	465
4.1.2.1.2	Flagellins	467
4.1.2.1.3	Heat Shock Proteins	468
4.1.2.1.4	Superoxide Dismutase	469
4.1.2.1.5	Adhesins	469
4.1.2.1.6	LPS	470
4.1.2.1.7	Others	471
4.1.2.2	Antigens Expressed Only in Type I Strains	471
4.1.2.2.1	CagA	471
4.1.2.2.2	VacA	472
4.1.2.3	Large Scale Production of Antigens	474
4.1.3.	Animal Models	474
4.1.3.1	Animal Models of Disease	474
4.1.3.2	Animal Models of Infection	476
4.1.4	Antigen Delivery and Mucosal Adjuvants	479
4.1.5	Vaccine Feasibility	482
	Acknowledgements	484
	References	484
4.2	Malaria Vaccination	497
	<i>Manuel E. Patarroyo and Roberto Amador</i>	
4.2.1	Introduction	497
4.2.2	Immunological Considerations for Malaria Vaccines	498
4.2.3	Novel Malaria Vaccine Approaches	500
4.2.4	Scenarios and Methods of Evaluation	501
4.2.5	Public Health Impact of the Malaria Vaccine Around the World	503
4.2.6	Conclusions	504
	Acknowledgements	505

References	505
4.3 Vaccination Against Schistosomiasis: Concepts and Strategies ...	509
<i>Gilles J. Riveau and André Capron</i>	
4.3.1 Introduction	509
4.3.2 Escape Mechanisms in Schistosomiasis	510
4.3.3 Effector Mechanisms in Experimental Models to Immunity in Humans	512
4.3.4 Target Antigens of Immunity	515
4.3.4.1 Surface Antigens	515
4.3.4.2 Antigens Identified Using Irradiated Cercariae Vaccine Model ...	516
4.3.4.3 Integral Membrane Proteins of Schistosomes	516
4.3.4.4 Enzymes of the Glycolytic Pathway	517
4.3.4.5 Excreted-Secreted Antigens	518
4.3.4.6 Paramyosin	519
4.3.4.7 Glutathione S-Transferases	519
4.3.5 Conceptual Basis of a Vaccine Strategy	521
4.3.6 New Approaches for Effective Vaccine Against Schistosomiasis .	523
4.3.7 Concluding Remarks	525
References	526
4.4 AIDS Vaccination	533
<i>Stephen Norley and Reinhard Kurth</i>	
4.4.1 Introduction	533
4.4.2 The Problem of Variability in the Development of an AIDS Vaccine	534
4.4.3 Possible Protective Immune Responses	535
4.4.3.1 Neutralising Antibody	535
4.4.3.2 Virolysis, Complement Mediated Lysis and Antibody-Dependent Cellular Cytotoxicity (ADCC)	536
4.4.3.3 Cytotoxic T-Lymphocytes (CTL)	537
4.4.4 Primate Models for AIDS Vaccine Development	537
4.4.4.1 HIV-1 Infection of Chimpanzees	537
4.4.4.2 SIV Infection of Macaques	538
4.4.4.3 HIV-2 Infection of Primates	539
4.4.5 Vaccine Strategies	539
4.4.5.1 Whole Inactivated Virus	539
4.4.5.2 Purified Recombinant Subunit Vaccines	541
4.4.5.3 Synthetic Peptide Immunogens	542
4.4.5.4 Live Vectors	542
4.4.5.5 Combination Vaccines	543
4.4.5.6 Live Attenuated Virus	544

Contents	XXI
4.4.5.7 Genetic Immunisation	545
4.4.6 Conclusions	547
References	548
4.5 Vaccination Therapy Against Autoimmune Diseases	559
<i>Irun R. Cohen and Felix Mor</i>	
4.5.1 Introduction	559
4.5.1.1 Vaccination, Tolerance and Autoimmune Disease	559
4.5.2 T Cell Vaccination	560
4.5.2.1 Specific Cell Vaccines	560
4.5.2.2 Complexities of T Cell Vaccination	561
4.5.2.3 Ergotypic Vaccination	562
4.5.2.4 TCR Peptide Vaccination	563
4.5.2.5 Clinical T Cell Vaccination	563
4.5.3 Vaccination with Autoantigens	564
4.5.3.1 Mucosal Vaccination	564
4.5.3.2 Peptide Vaccination	565
4.5.3.3 The Importance of the Adjuvant	567
4.5.4 The Future	568
Acknowledgements	568
References	568
Contributors	573